

# TSH-Secreting Pituitary Adenoma Identified in Pregnancy: Management of an Unusual Case

## Case History:

35 year old Columbian lady. Routine blood tests by GP due to impaired fertility showed hyperthyroidism with high TSH.


- At time of clinic appointment, 7/40 after natural conception
- Migrainous headaches in early pregnancy, and vague history of palpitations, but no clear symptoms of hyperthyroidism
- No personal/family Hx of thyroid/pituitary problems
- Ex: completely unremarkable
- 2 days before Christmas




**Pre-conception:**  
free T4 **30.8 pmol/L**  
free T3 **7.5 pmol/L**  
TSH **5.1 mIU/L**

## MRI Pituitary: Enlarged asymmetrical pituitary

(Performed on Christmas Eve, at 7/40 gestation)



**MRI Limitations:** Statistically significant increase in pituitary dimensions at all stages of pregnancy (p <0.001)




Gonzalez JG, et al. Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging. Am J Med. 1988 Aug;85(2):217-20.

## Biochemistry:


	2/11/11	23/12/2011	Ref. Lab 21/12/2011	3/01/2012
<b>TSH</b>	<b>5.1</b>	<b>5.7</b>	4.84 (0.35-5)	<b>5.3</b>
<b>T4</b>	<b>30.6</b>	<b>25.0</b>	<b>23.4 (9-19.1)</b>	<b>24.2</b>
<b>T3</b>	<b>7.5</b>	<b>6.6</b>	<b>6.4 (2.6-5.7)</b>	<b>6.7</b>
<b>TRAb</b>		<1		
<b>Anti-TPO</b>		<b>967</b>		
<b>Heterophile Ab</b>		Negative		

## Results of investigations difficult to interpret due to pregnancy:

- Prolactin **722** mIU/L (normal range outside pregnancy <700)
- SHBG **209** nmol/L (normal range outside pregnancy 20-130)
- LH and FSH **fully suppressed**
- Alpha-subunit: **>24** ug/L (normal range outside pregnancy <1)
- **Thyroid Hormone Resistance Syndrome: Negative**  
(but 15% have no detectable mutations)



## Biochemistry through pregnancy:



## Post partum results

Thyroid function monitored 2 weekly through pregnancy. Biochemistry throughout pregnancy remained stable. A healthy baby boy was delivered after a normal vaginal delivery. His thyroid function tests are all within the normal range. Our patient remained asymptomatic despite an elevation in her free thyroid hormones post partum

## Past experience of management:

### TSH secreting Pituitary Adenoma in Pregnancy

3 case reports (all diagnosed preconception). In all cases, pituitary enlargement associated with visual symptoms (3rd trimester). Different management pathways in each report:

1. Continuous subcutaneous octreotide 300mcg/day<sup>2</sup>
2. Intermittent subcutaneous octreotide<sup>3</sup>
3. PTU, bromocriptine and decompressive surgery<sup>4</sup>


### Management of TSH Producing Pituitary Tumours Outside of Pregnancy<sup>5</sup>:

1. **Anti-thyroid medications not considered effective:**  
unless concurrent autoimmune disease
2. **Somatostatin analogues:** most commonly used.  
(cure possibly influenced by somatostatin receptor subtype<sup>6</sup>)  
*Biochemical cure (T4/T3 normalisation) in ~75%*  
*TSH improvement in ~90%*  
*Tumour shrinkage in ~33%*
3. **Dopamine agonists**  
less efficacious UNLESS mixed TSH/Prolactin secretion
4. **Transphenoidal surgery:**  
Further surgery required in up to 20%
5. **Alternative management:**  
Thyroid ablation (surgery/radioactive iodine; n=2),  
no changes in pituitary size over 8 and 12 years of follow up<sup>7</sup>

### Thyroid Hormone Resistance and Pregnancy

- Ideal management pathway remains unclear<sup>1</sup>
- Patients typically asymptomatic unless selective pituitary thyroid hormone resistance present
- Challenges surrounding how to manage the metabolic status of the fetus when it is at odds with maternal metabolic environment.
- Issues regarding frequency of fetal monitoring and intrauterine diagnosis.

## MRI Pituitary Post Partum: Unchanged



Dimensions of the pituitary adenoma post partum are unchanged from the original MRI performed during the first trimester

## Results additional investigations post-partum:

- Prolactin 545 mIU/L (normal)
- SHBG 120 nmol/L (normal)
- LH 8.1 and FSH 8.8 (normal)
- Alpha-subunit: **4.95** ug/L (elevated)

## Ongoing Management Plan:

Our patient would like to have further pregnancies. She is scheduled to have transphenoidal pituitary surgery for removal of the adenoma in March 2013.

## References:

1. Gonzalez JG, et al. Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging. Am J Med. 1988 Aug;85(2):217-20.
2. Chaïamnuay S, Moster M, Katz MR, et al. Successful management of a pregnant woman with a TSH secreting pituitary adenoma with surgical and medical therapy. Pituitary. 2003 Sep;6(2):109-13.
3. Blackhurst G, Strachan MW, Collie D, et al. The treatment of a thyrotropin-secreting pituitary macroadenoma with octreotide in twin pregnancy. Clin Endocrinol (Oxf). 2002 Sep;57(3):401-4.
4. Caron P, Gerbeau C, Pradayrol L, et al. Successful pregnancy in an infertile woman with a thyrotropin-secreting macroadenoma treated with somatostatin analog (octreotide). JCEM. 1996 Mar;81(3):1164-8.
5. Socin HV, Chanson P, Delemer B, et al. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol. 2003 Apr;148(4):433-42.
6. Yoshihara A, Isozaki O, Hizuka N, et al. Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting long-term response to octreotide therapy. Endocr J. 2007 Feb;54(1):133-8.
7. Daousi C, Foy PM, Macfarlane IA. Ablative thyroid treatment for thyrotoxicosis due to thyrotropin-producing pituitary tumours. BMJ Case Rep. 2009;2009. pii: bcr07.2008.0541.